Your session is about to expire
← Back to Search
Selinexor for Glioblastoma
Study Summary
This trial will study the effects of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma. The study will be conducted in 2 phases and will evaluate 3 different combination regimens in 3 treatment arms.
- Glioblastoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 116 Patients • NCT02025985Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What maladies does Selinexor typically alleviate?
"Selinexor is routinely used for disease progression, yet it can also be helpful in the management of malignant neoplasms, recurrent platinum sensitive primary peritoneal cancer and other end-of-life directives."
Could you please provide a synopsis of prior experiments related to Selinexor?
"Selinexor was first trialled at City of Hope Medical Center in the year 2000, and 1381 trials have been finished. Currently 632 studies are on-going; a large proportion being conducted within New york and Massachusetts."
How many health centers in this city are administering the research?
"To make it easier for participants, this medical trial is enrolling patients at a grand total of 18 sites. The facilities are located in cities such as New york, Boston and Seattle alongside other locales. Should you choose to join the study, selecting the closest option can help reduce your travel requirements."
What is the upper limit of individuals partaking in this trial?
"The sponsor, Karyopharm Therapeutics Inc., requires 474 eligible participants to carry out this trial. There are multiple sites located in New york, Massachusetts, Boston and Washington where the study is being conducted - such as Columbia University Irving Medical Center and Dana Farber Cancer Institute."
Is enrollment currently open for this research experiment?
"Confirmed, the clinical trial is still open for enrollment. It was first listed on the 8th of June 2020 and underwent its last revision on April 1st 2021."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- University of Washington - Alvord Brain Tumor Center: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger